ONC BeiGene Ltd.
Price (delayed)
$274.78
Market cap
$29.35B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.47
Enterprise value
$27.81B
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R)
Highlights
The company's gross profit has surged by 55% YoY and by 16% QoQ
The revenue has soared by 55% YoY and by 15% from the previous quarter
BeiGene's quick ratio has decreased by 24% YoY and by 8% QoQ
BeiGene's debt has increased by 16% YoY
Key stats
What are the main financial stats of ONC
Market
Valuations
Earnings
Shares outstanding
106.83M
Market cap
$29.35B
Enterprise value
$27.81B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.8
Price to sales (P/S)
7.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.3
Revenue
$3.81B
Gross profit
$3.22B
Operating income
-$568.2M
Net income
-$644.79M
EBIT
-$580.84M
EBITDA
-$409.08M
Free cash flow
-$633.29M
Per share
Balance sheet
Liquidity
EPS
-$0.47
EPS diluted
-$0.47
Free cash flow per share
-$6.01
Book value per share
$31.22
Revenue per share
$36.15
TBVPS
$55.69
Total assets
$5.92B
Total liabilities
$2.59B
Debt
$1.08B
Equity
$3.33B
Working capital
$1.78B
Debt to equity
0.32
Current ratio
1.8
Quick ratio
1.49
Net debt/EBITDA
3.78
Margins
Efficiency
Dividend
EBITDA margin
-10.7%
Gross margin
84.4%
Net margin
-16.9%
Operating margin
-14.9%
Return on assets
-11.1%
Return on equity
-19.1%
Return on invested capital
-27.4%
Return on capital employed
-15.7%
Return on sales
-15.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ONC stock price
How has the BeiGene stock price performed over time
Intraday
1.38%
1 week
9.51%
1 month
1.1%
1 year
79.3%
YTD
48.76%
QTD
0.96%
Financial performance
How have BeiGene's revenue and profit performed over time
Revenue
$3.81B
Gross profit
$3.22B
Operating income
-$568.2M
Net income
-$644.79M
Gross margin
84.4%
Net margin
-16.9%
ONC's operating margin has surged by 70% year-on-year and by 43% since the previous quarter
The company's gross profit has surged by 55% YoY and by 16% QoQ
The revenue has soared by 55% YoY and by 15% from the previous quarter
BeiGene's net margin has soared by 53% YoY and by 35% from the previous quarter
Growth
What is BeiGene's growth rate over time
Valuation
What is BeiGene stock price valuation
P/E
N/A
P/B
8.8
P/S
7.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.3
The company's EPS rose by 28% YoY and by 27% QoQ
The price to book (P/B) is 58% higher than the last 4 quarters average of 5.5 and 55% higher than the 5-year quarterly average of 5.6
The equity has contracted by 6% YoY and by 3% from the previous quarter
ONC's price to sales (P/S) is 70% lower than its 5-year quarterly average of 25.4 but 29% higher than its last 4 quarters average of 5.8
The revenue has soared by 55% YoY and by 15% from the previous quarter
Efficiency
How efficient is BeiGene business performance
The company's return on sales has surged by 58% YoY and by 41% QoQ
BeiGene's ROIC has increased by 50% YoY and by 35% from the previous quarter
The company's return on assets rose by 27% YoY and by 26% QoQ
ONC's return on equity is up by 24% since the previous quarter and by 17% year-on-year
Dividends
What is ONC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ONC.
Financial health
How did BeiGene financials performed over time
The total assets is 129% greater than the total liabilities
BeiGene's quick ratio has decreased by 24% YoY and by 8% QoQ
The current ratio is down by 22% year-on-year and by 7% since the previous quarter
BeiGene's debt is 68% less than its equity
BeiGene's debt to equity has increased by 23% YoY
BeiGene's debt has increased by 16% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.